Previous 10 | Next 10 |
MyoKardia (NASDAQ: MYOK ): Q3 GAAP EPS of -$3.07 misses by $1.06 . More news on: MyoKardia, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019. “As we look across the milestones recently achieved and those just ahead, we see steady progress on our near- a...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA) Scientific Sessions taking place November 16 – November 18, 2019 in Philadelphia, Penn...
MyoKardia ( MYOK -0.5% ) announces positive preliminary data from a Phase 2a clinical trial evaluating MYK-491 in patients with stable heart failure due to the inability of the left ventricle to pump blood effectively. More news on: MyoKardia, Inc., Healthcare stocks news, Read m...
Interim Data Demonstrated Favorable Safety and Activity Profile in Phase 2a Multiple-Ascending Dose Study Phase 2 Clinical Trial in Targeted Segment of Genetic DCM to Initiate in 1H 2020 SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), ...
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019, at 4:10 p.m. ET in N...
MKM partners initiates coverage on seven pot stocks: Curaleaf Holdings ( OTCPK:CURLF ): Sell, Aurora Cannabis (NYSE: ACB ): Sell ( -1% ), Canopy Growth (NYSE: CGC ): Neutral (up a fraction), Tilray (NASDAQ: TLRY ): Neutral (up a fraction), Cronos Group (NASDAQ: CRON ): Neutral ( +1% ), ...
The following slide deck was published by MyoKardia, Inc. in conjunction with this Read more ...
MyoKardia ( MYOK -1.2% ) plans to launch a study in H1 2020 evaluating lead drug mavacamten as an alternative to septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (HCM), a disorder in which the heart muscle becomes abnormally thick making it harder f...
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study will be conducted at leading HCM centers that regularly perform surgical my...
News, Short Squeeze, Breakout and More Instantly...
EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten T reatment Resulted in Favorable Effect on Cardiac Structure -- Significantly Reduced Hypertrophy in Patien...
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with ...
BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovas...